Here's something you might be interested in.
Ask a Hipster — Advice you didn't know you needed
Big Screen — Movie commentary
Blurt — Music's inside track
Booze News — San Diego spirits
Classical Music — Immortal beauty
Classifieds — Free and easy
Cover Stories — Front-page features
Drinks All Around — Bartenders' drink recipes
Excerpts — Literary and spiritual excerpts
Feast! — Food & drink reviews
Feature Stories — Local news & stories
Fishing Report — What’s getting hooked from ship and shore
From the Archives — Spotlight on the past
Golden Dreams — Talk of the town
The Gonzo Report — Making the musical scene, or at least reporting from it
Letters — Our inbox
Movies@Home — Local movie buffs share favorites
Movie Reviews — Our critics' picks and pans
Musician Interviews — Up close with local artists
Neighborhood News from Stringers — Hyperlocal news
News Ticker — News & politics
Obermeyer — San Diego politics illustrated
Outdoors — Weekly changes in flora and fauna
Overheard in San Diego — Eavesdropping illustrated
Poetry — The old and the new
Reader Travel — Travel section built by travelers
Reading — The hunt for intellectuals
Roam-O-Rama — SoCal's best hiking/biking trails
San Diego Beer — Inside San Diego suds
SD on the QT — Almost factual news
Sheep and Goats — Places of worship
Special Issues — The best of
Street Style — San Diego streets have style
Surf Diego — Real stories from those braving the waves
Theater — On stage in San Diego this week
Tin Fork — Silver spoon alternative
Under the Radar — Matt Potter's undercover work
Unforgettable — Long-ago San Diego
Unreal Estate — San Diego's priciest pads
Your Week — Daily event picks
Isis stock soars on positive data
Biotech's treatment does well in early stages
San Diego biotech Isis Pharmaceuticals announced before market opening this morning (February 21) that it has had very successful results in early-stage tests for its experimental treatment for spinal muscular atrophy in children.
The stock closed at $59, up 15.53 percent. Its rise is pushing the entire biotech sector up.
Isis has a licensing deal with Cambridge, Massachusetts-based Biogen Idec, which makes regular milestone payments to Isis. The Idec portion of Biogen Idec was formed in San Diego, but then merged with Biogen.
In 2010, the parent company said it was closing down its local operations, resulting in a loss of more than 300 local jobs.
Here's something you might be interested in.
Isis stock soars on positive data
Biotech's treatment does well in early stages
Isis stock soars on positive data
Biotech's treatment does well in early stages
San Diego biotech Isis Pharmaceuticals announced before market opening this morning (February 21) that it has had very successful results in early-stage tests for its experimental treatment for spinal muscular atrophy in children.
The stock closed at $59, up 15.53 percent. Its rise is pushing the entire biotech sector up.
Isis has a licensing deal with Cambridge, Massachusetts-based Biogen Idec, which makes regular milestone payments to Isis. The Idec portion of Biogen Idec was formed in San Diego, but then merged with Biogen.
In 2010, the parent company said it was closing down its local operations, resulting in a loss of more than 300 local jobs.
Comments